1.1 The Endothelin Pathway

Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor in human biology — roughly 100-fold more potent than norepinephrine on a molar basis. Vascular endothelium synthesizes ET-1 in response to shear stress, hypoxia, angiotensin II, vasopressin, and inflammatory cytokines. Its actions are mediated by two G-protein-coupled receptors:

• ETA receptor: Vascular smooth muscle. Mediates vasoconstriction, proliferation, fibrosis, aldosterone release, and sympathetic activation. The “bad guy” of the pathway in chronic HTN and CKD pathophysiology.
• ETB receptor: Endothelial cells (NO and prostacyclin release — vasodilation), renal tubules (natriuresis, water excretion), pulmonary clearance of circulating ET-1. Largely counter-regulatory — the “good guy” in normal physiology.

1.2 Aprocitentan Specifics

Aprocitentan is the active metabolite of macitentan (the pulmonary arterial hypertension drug). Idorsia recognized that macitentan’s metabolite had the right pharmacokinetics for once-daily oral systemic HTN dosing:

The non-CYP metabolism is a significant advantage in nephrology populations who are already on multiple drugs. No interaction with statins, no interaction with calcineurin inhibitors, no interaction with the dihydropyridines or thiazides used as background therapy.

1.3 Why Endothelin Antagonism Took 20 Years to Reach HTN Approval

Bosentan (the first dual ERA, approved for PAH in 2001) was tried in HTN and failed on hepatotoxicity. Darusentan (selective ETA) reached Phase 3 in resistant HTN — DORADO and DORADO-AC — and missed primary endpoints with significant edema. Atrasentan in DKD nearly killed the program when SONAR was stopped early for HF events. The lesson the field learned: dose matters, patient selection matters, and the fluid retention signal is unforgiving in HF-prone populations.

Aprocitentan’s case rests on three engineering choices: dose-titrated low (12.5 mg start), dual blockade to preserve some natriuretic effect, and patient selection that explicitly excluded HF (NYHA III-IV) in PRECISION.

flowchart LR
    A[Endothelin-1 Release] --> B[ETA Receptor]
    A --> C[ETB Receptor]
    B --> D[Vasoconstriction<br/>Fibrosis<br/>Aldosterone Release]
    C --> E[NO Release<br/>Natriuresis<br/>ET-1 Clearance]
    F[Aprocitentan] -.blocks.-> B
    F -.blocks.-> C
    D -.suppressed.-> G[BP Lowering]
    E -.partially suppressed.-> H[Fluid Retention<br/>Side Effect]
    style F fill:#ffe066
    style G fill:#a3e4d7
    style H fill:#f5b7b1

2.1 PRECISION Design (Schlaich et al., Lancet 2022, PMID 36356632)

According to PubMed, PRECISION was a multicenter, blinded, randomized, parallel-group, phase 3 trial designed in three sequential parts to test both short-term BP lowering and durability of effect #ref1.

2.2 The Pseudoresistance Lesson (The Most Important Finding Most People Miss)

PRECISION screened 1,965 patients referred for resistant HTN. After the screening process — switching to a single-pill triple combination, requiring 4 weeks of confirmed adherence, and confirming office SBP remained ≥140 — only 730 patients (37.2%) met criteria for randomization.

This is not a footnote. The Danaietash 2022 baseline paper (PMID 35686330) #ref2 explicitly framed pseudoresistance as a major finding of the screening process — and it should change clinical practice independent of whether you ever prescribe aprocitentan.

2.3 Primary Endpoint Results

Office SBP change at week 4:

Both doses beat placebo by approximately 4 mmHg office SBP. The 25 mg dose did not produce greater BP lowering than the 12.5 mg dose at week 4 — this is unusual for an antihypertensive and supports starting at 12.5 mg as the default.

24-hour ABPM SBP change at week 4 (placebo-corrected):

The ABPM signal is larger than the office signal, particularly at 25 mg, suggesting the office measurement underestimates the true effect. ABPM also revealed that the 25 mg dose has incremental nocturnal BP control that the office measurement missed. Bottom line: 12.5 mg is the right starting dose; 25 mg gives meaningful additional ABPM benefit but comes with double the edema risk.

2.4 The Withdrawal Phase — Persistence of Effect

Part 3 of PRECISION re-randomized patients at week 36 to either continued 25 mg aprocitentan or placebo for 12 weeks. After 4 weeks of withdrawal, office SBP rose 5.8 mmHg in the placebo arm vs the aprocitentan arm (95% CI 3.7–7.9, P<0.0001) — confirming the drug-attributable effect was sustained at 40 weeks of treatment and fades when you stop it.

2.5 Safety Profile

The hemoglobin signal is real but small. Class effect from endothelin antagonism — modest hemodilution from fluid shift plus mild RBC hemolysis effects. PRECISION did not show clinically significant anemia requiring intervention.

Hepatotoxicity: PRECISION did not demonstrate the bosentan-class hepatotoxicity signal. Despite this, FDA approval included REMS-style monthly LFT monitoring for the first treatment year in early labeling — driven by class precedent rather than aprocitentan-specific data.

3.1 The Resistant HTN Add-On Hierarchy

Per current AHA/ACC/AHA expert consensus and KDIGO 2021 BP guidance for CKD, after three-drug therapy with ACEi/ARB + CCB + thiazide, the fourth-line options are:

1. MRA (spironolactone) — PATHWAY-2 evidence; placebo-corrected SBP −8.7 mmHg in true resistant HTN. Limited in CKD by hyperkalemia.
2. MRA (eplerenone) — Less hyperkalemia, lower potency, often used after spironolactone gynecomastia.
3. Beta-blocker — Especially useful in hyperadrenergic phenotype, post-MI, HF.
4. Alpha-blocker (doxazosin) — Especially useful with BPH overlap.
5. Centrally-acting (clonidine, methyldopa) — Last resort, tolerability issues.
6. Loop diuretic — Essential when GFR <30 (thiazides lose potency).
7. Aprocitentan — New entrant. Particularly attractive when MRAs are contraindicated.
8. Renal denervation — Procedural option after failed pharmacologic optimization.

3.2 Comparison Table — Aprocitentan vs Spironolactone vs Renal Denervation vs Baxdrostat

3.3 The Honest Comparison — Magnitude of Effect

The placebo-corrected SBP reduction from each option is:

• Spironolactone (PATHWAY-2): approximately −8 to −9 mmHg office
• Baxdrostat (BaxHTN Phase 3): approximately −9 mmHg office
• Aprocitentan (PRECISION): approximately −4 mmHg office, −6 mmHg ABPM 25 mg
• Renal denervation (RADIANCE-HTN TRIO): approximately −5 mmHg ABPM
• Lorundrostat (Launch-HTN): approximately −7 mmHg office (data still maturing)

4.1 The Combination With SGLT2i

The most rational future trial design — and the position taken by Smeijer/Heerspink in Nat Rev Nephrol — is endothelin antagonist + SGLT2i as a combination strategy. SGLT2i provides natriuresis and intravascular volume reduction that can offset the fluid retention liability of endothelin blockade. The ZENITH-CKD trial of zibotentan + dapagliflozin demonstrated this synergy in proof-of-concept. No equivalent aprocitentan + SGLT2i combination trial has been reported as of this writing. This is the obvious next study, but until it exists, combination is empirical.

5.1 Patient Selection

Best candidate: - True resistant HTN confirmed by ABPM - Already on optimized triple therapy (ACEi/ARB + DHP-CCB + thiazide or thiazide-like) - Adherence verified (single-pill combinations, pharmacy data, witnessed dosing) - Pseudoresistance ruled out (proper measurement, secondary cause workup completed) - MRA contraindicated by hyperkalemia OR has caused gynecomastia OR has failed at maximum tolerated dose - No history of HF (HFrEF or HFpEF) - No active liver disease - Female of reproductive potential has reliable contraception OR not at risk of pregnancy

Avoid: - Any HF history (HFrEF, HFpEF, NYHA II–IV) - Pregnancy or potential pregnancy without contraception plan - Moderate-to-severe hepatic impairment - Severe anemia (Hb <10) at baseline - Patients who cannot do monthly LFT monitoring

5.2 Dosing

5.3 Monitoring

5.4 What to Do If Edema Develops

1. Mild edema (trace pitting, no symptomatic worsening): Continue, recheck in 2 weeks. Add or up-titrate loop diuretic if not already on one.
2. Moderate edema (>1+ pitting, weight gain >2 kg, dyspnea): Hold aprocitentan. Diurese. Reassess HF risk. Consider rechallenge at 12.5 mg if event was clearly fluid retention without HF.
3. Severe edema or any HF symptoms: Discontinue permanently. Rule out incident HF. Do not rechallenge.

5.5 The Cost Conversation

Aprocitentan list price is approximately $22,000 per year in the US. For a patient already on optimized polytherapy who would otherwise face procedural intervention or institutional placement for uncontrolled BP, the cost is justifiable. For a patient who has not had a real adherence intervention, this is a $22,000/year solution to a $0 adherence problem.

Insurance coverage: Most plans require step therapy through MRA (spironolactone or eplerenone) and documentation of either failure or hyperkalemia. Prior authorization is the norm — the /prior auth skill is built for exactly this conversation.